Not an actual patient.

CONSISTENT, RELIABLE, AND LONG-ACTING T SUPPRESSION ENABLED BY THE PROPRIETARY DELIVERY SYSTEM OF ELIGARD^®

Unique in situ polymeric extended-release delivery system enables sustained and controlled release of leuprolide acetate as it safely biodegrades¹

In Situ Polymeric Gel Extended-Release Delivery Technology²

Drug

leuprolide acetate

Biodegradable copolymer

PLG copolymer

Biocompatible liquid carrier

N-methyl-2-pyrrolidone (NMP)

PLG COPOLYMER SOLIDIFIES IN THE BODY DUE TO EXCHANGE OF NMP AND WATER IN TISSUE FLUID AND FORMS A SOLID IN SITU¹

After injection, ELIGARD solidifies into a solid, pea-sized pearl. Let your patients know they may feel a tiny bump immediately after injection. The bump reduces in size over time¹

ELIGARD being injected into SC tissue and solidifying in situ.

ELIGARD in situ, slowly biodegrading over the dosing period.

THE ELIGARD PRE-CONNECTED SYRINGE SYSTEM (EPSS) PROMOTES EFFICIENCY WITH JUST ONE CLICK²

Preparation and administration

Prepare

If refrigerated, allow the product to reach room temperature (59-86 °F) before using

Mix

Thoroughly mix ELIGARD by pushing the liquid to powder back and forth for 60 cycles between syringes to obtain a uniform suspension

Administer

Inject ELIGARD at a 90° angle into subcutaneous tissue

Ensuring the proper injection angle enables accurate extended-release delivery

SINCE ELIGARD IS NOT A COMPOUNDED PRODUCT, USP 800 GUIDELINES DO NOT APPLY TO THE MIXING AND ADMINISTRATION³

Get more support for ELIGARD mixing & administration

Helpful videos, guides, and training sessions can help you with ELIGARD mixing & administration

MIXING & ADMINISTRATION VIDEO

MIXING & ADMINISTRATION GUIDE

JOIN OUR WEEKLY VIRTUAL MIXING & ADMINISTRATION TRAINING SESSIONS

Virtual training sessions include a demonstration of the mixing and administration of ELIGARD. The clinical trainer will answer any questions you may have.

To ensure your team is confident in the optimal way to mix and administer treatment, your ELIGARD account representative can provide an in-person in-service

ELIGARD Can be left at room temperature for up to 8 weeks (56 days) prior to mixing²

Storing ELIGARD

ELIGARD is a refrigerated product and should be stored at 2 °C to 8 °C (36-45 °F) but can be left at room temperature for up to 8 weeks (56 days) prior to mixing and administration²

ELIGARD can be re-refrigerated once, if out of the fridge for under 48 hours, without affecting its shelf life⁴

30-minute administration time limit

If the product is NOT administered within 30 minutes of mixing, it must be discarded²

ELIGARD cannot be re-refrigerated if it has already been mixed or has already been re-refrigerated once⁴

The flexibility in eligard storage offers more advantages for your practice

ELIGARD OFFERS UNMATched access & support, GIVING you and your patients more

PLG, poly(lactic-co-glycolic acid); SC, subcutaneous; T, testosterone.

References: 1. Sartor O. Eligard^®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910. 2. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 3. Data on file. Tolmar, Inc. 2024. 4. Data on file. Tolmar, Inc. 2024.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Steve-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.

CONSISTENT, RELIABLE, AND LONG-ACTING T SUPPRESSION ENABLED BY THE PROPRIETARY DELIVERY SYSTEM OF ELIGARD®

In Situ Polymeric Gel Extended-Release Delivery Technology2